Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. by Yao, Wei et al.
UC Davis
UC Davis Previously Published Works
Title
Overexpression of secreted frizzled-related protein 1 inhibits bone formation and 




Journal of bone and mineral research : the official journal of the American Society for 














eScholarship.org Powered by the California Digital Library
University of California
ORIGINAL ARTICLE JBMR
Overexpression of Secreted Frizzled-Related Protein 1
Inhibits Bone Formation and Attenuates Parathyroid
Hormone Bone Anabolic Effects
Wei Yao ,1 Zhiqiang Cheng ,1 Mohammad Shahnazari ,1 Wewei Dai ,1 Mark L Johnson ,2 and
Nancy E Lane1
1Department of Medicine, UC Davis Medical Center, Sacramento, CA, USA
2Department of Oral Biology, UMKC School of Dentistry, Kansas City, MO, USA
ABSTRACT
Secreted frizzled-related protein 1 (sFRP1) is an antagonist of Wnt signaling, an important pathway in maintaining bone homeostasis. In
this study we evaluated the skeletal phenotype of mice overexpressing sFRP1 (sFRP1 Tg) and the interaction of parathyroid hormone
(PTH) treatment and sFRP1 (over)expression. Bone mass and microarchitecture were measured by micro-computed tomography (mCT).
Osteoblastic and osteoclastic cell maturation and function were assessed in primary bone marrow cell cultures. Bone turnover was
assessed by biochemical markers and dynamic bone histomorphometry. Real-time PCR was used to monitor the expression of several
genes that regulate osteoblast maturation and function in whole bone. We found that trabecular bone mass measurements in distal
femurs and lumbar vertebral bodies were 22% and 51% lower in female and 9% and 33% lower in male sFRP1 Tg mice, respectively,
compared with wild-type (WT) controls at 3 months of age. Genes associated with osteoblast maturation and function, serum bone
formation markers, and surface based bone formation were significantly decreased in sFRP1 Tgmice of both sexes. Bone resorption was
similar between sFRP1 Tg and WT females and was higher in sFRP1 Tg male mice. Treatment with hPTH(1-34) (40mg/kg/d) for 2 weeks
increased trabecular bone volume in WT mice (females: þ30% to 50%; males: þ35% to 150%) compared with sFRP1 Tg mice (females:
þ5%; males: þ18% to 54%). Percentage increases in bone formation also were lower in PTH-treated sFRP1 Tgmice compared with PTH-
treated WT mice. In conclusion, overexpression of sFRP1 inhibited bone formation as well as attenuated PTH anabolic action on bone.
The gender differences in the bone phenotype of the sFRP1 Tg animal warrants further investigation. 2010 American Society for Bone
and Mineral Research.
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The wingless and Int1 (Wnt) family of secreted proteinsregulates many aspects of cell growth, differentiation, and
death during both embryogenesis and adult life.(1) The crucial
role of Wnt signaling in mammalian bone homeostasis has been
recognized in recent years.(2,3) Both canonical and noncanonical
pathways are involved in coordinating proper bone develop-
ment, formation, and growth during pre- and postnatal
periods.(4,5) Canonical Wnt/b-catenin signaling supports osteo-
genic differentiation from mesenchymal stem cells (MSCs).
During in vivo bone development, Wnt/b-catenin signaling
prevents MSCs from differentiating into chondrocytes(6) and
promotes osteoblast differentiation.(7) b-Catenin signaling in
differentiated osteoblasts has been shown to negatively controlReceived in original form February 2, 2009; revised form May 4, 2009; accepted Ju
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190osteoclast formation and bone resorption through an increase in
osteoprotegerin production by osteoblasts.(8) Similar to other
growth factors, Wnt signaling can be antagonized by secreted or
intracellular inhibitors. Several known Wnt signaling inhibitors
include secreted frizzled-related proteins (sFRPs), Wnt inhibitor
factor I (WifI), the Dickkopf proteins (Dkks), and sclerostin
(product of Sost gene). The sFRPs consist of at least seven
members in vertebrates (sFRP1 to sFRP5, crescent, and sizzled)
and contain a frizzled (Fz)–related cysteine-rich domain that can
bind to both Wnt proteins and Fz but lack the intracellular
sequence found in the Fz receptors. The sFRPs antagonize Wnt
function by binding to the Wnt proteins and preventing Wnt/
receptor activation. There is evidence to support the ability of
sFRPs to inhibit both canonical and noncanonical Wnt signal-
ing.(9) Overexpression of sFRP1 in human osteoblasts has beenly 6, 2009. Published online July 13, 2009.
alifornia at Davis Medical Center, Sacramento, CA 94110, USA.
Fig. 1. (A) Representative genotyping for sFRP1. The sFRP1 transgenic
mice (Tg) PCR product gives two bands at 1 kb (Actin) and 300 bp (EGFP),
whereas wild-type (WT) mice have one band at 1 kb. (B) Proteins were
extracted and analyzed by immunoblotting with antibodies against
sFRP1 in selected tissues. GAPDH was used as a control. (C) Relative
quantitative measurement of sFRP1 levels in selected tissues from both
WT and sFRP1 Tg female and male mice. ap< .05 from the WT mice.reported to accelerate the rate of osteoblast and osteocyte
death.(10) Adult mice deficient in sFRP1 showed resistance to
age-related bone loss.(11) The lack of sFRP1 in mice resulted in
decreases in osteoblast and osteocyte apoptosis.(10) sFRP1
knockout mice also have reduced bone anabolic responses
to parathyroid hormone (PTH) treatment.(12) In addition to
osteoblastogenesis, sFRP1 affects osteoclastogenesis because
sFRP1 can directly bind RANKL(13) and/or inhibit the fusion of
mononuclear cells,(14) thereby inhibiting osteoclast formation.
Despite broad tissue distribution, ablation of sFRP1 in mice did
not affect blood and urine markers of bone resorption or organ
function in most nonskeletal tissues.(11) Recently, a small
molecule inhibitor (diarylsulfone sulfonamide) that can bind
and inhibit sFRP1 was shown to stimulate bone formation,(15)
suggesting that inhibition of sFRP1 may be a potential target to
stimulate Wnt signaling to increase bone formation.
Since Wnt signaling is critical for osteoblast maturation,
skeletal acquisition, and maintenance, we hypothesized that
overexpression of sFRP1 in sFRP1 transgenic mice (sFRP1 Tg)
would reduce osteoblast number and activity such that these
animals would have lower peak bone mass and reduced bone
acquisition. Further, we were interested in the effect of PTH
treatment in sFRP1 Tg mice.
Materials and Methods
Generation of the mice and experimental protocol
The sFRP1 Tg mice used for this research project, STOCK
Tg(sFRP1-EGFP)142Gsat/Mmcd and identification number
011017-UCD, were obtained from the Mutant Mouse Regional
Resource Center (MMRRC), a National Center for Research
Resource (NCRR)-National Institutes of Health (NIH)–funded
strain repository and were donated to the MMRRC by the
National Institute of Neurological Disorders and Stroke (NINDS)-
funded Gene Expression Nervous System ATLas (GENSAT)
engineering bacterial artificial chromosomes (BAC) transgenic
project. The genotype has been modified to contain multiple
copies of a modified BAC in which an EGFP reporter gene is
inserted immediately upstream of the coding sequence of the
sFRP1 gene, producing site-specific expression of green
fluorescent protein (GFP) in the gene of interest (sFRP1). EGFP
expression is sFRP1-promoter driven. The genetic background of
the sFRP1 Tgmouse was an FVB/N-Swiss Webster hybrid.(16) Mice
genotypes were confirmed by a PCR protocol with a GFP R2
primer (TAGCGG CTGAAGCACTGC A). An actin primer was
included in all PCR for genotyping. Electrophoresis was
performed in 2% agarose gel at 90 V for 90 minutes. Wild-
type (WT) mice had one band at 1000 bp for actin, whereas sFRP1
Tg mice had two bands at 1000 bp (actin) and at about 300 bp
(sFRP1-EGFP fuse protein), respectively (Fig. 1A).
During the experiments, the mice were maintained on
commercial rodent chow (Rodent Diet, Teklad, Madison, WI,
USA) available ad libitum with 0.95% calcium and 0.67%
phosphate. Mice were housed in a room that was maintained
at 70 8F with a 12 hour light/dark cycle. All animals were treated
according to the US Department of Agriculture (USDA) animal
care guidelines with the approval of the UC Davis Committee on
Animal Research.OVEREXPRESSION OF SFRP1 INHIBITS BONE FORMATIONAt 12 weeks of age, both female andmale WT or sFRP1 Tgmice
were treated subcutaneously with either vehicle [phosphate-
buffered daline (PBS)] (n¼ 10 to 11) or 40mg/kg human
PTH(1-34) (n¼ 12) (Bachem Bioscience, Inc., Torrance, CA,
USA) 5/week for 2 weeks. For all study animals, fluoro-
chrome labeling with alizarin red (20mg/kg s.c.) and calcein
(10mg/kg s.c.) were given 7 and 2 days before sacrifice to assess
bone formation. Mice were killed by exsanguination from the
heart at 14 weeks of age. Serum samples were obtained and
were stored at 808C prior to assessment of biochemical
markers of bone turnover. The right femurs and fifth lumbar
vertebral bodies were placed in 10% phosphate-buffered
formalin for 24 hours and subsequently transferred to 70%
ethanol for micro-computed tomography (mCT) and bone
histomorphometry. The calvaria, lung, heart, liver, spleen,
duodenum, kidney, left femurs, left tibiae, and ovaries or testes
were collected for protein or RNA extractions for Western blot
and real-time PCR analysis.
mCT
The right distal femur from each of the animals was scanned
using mCT (VivaCT 40, Scanco Medical, Bassersdorf, Switzerland)
with an isotropic resolution of 10mm in all three spatialJournal of Bone and Mineral Research 191
dimensions. The scan was initiated at the lateral periosteal
margin through the medial periosteal margin of the distal femur
and 0.1 mm from the highest part of the growth plate continuing
proximally for 2mm. Mineralized bone was separated from
the bone marrow with a matching-cube 3D segmentation
algorithm. A normalized index, trabecular bone volume/total
volume (BV/TV), was used to compare samples of varying sizes.
Trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and
trabecular number (Tb.N) also were calculated as we described
previously.(17–19)
Biochemical markers of bone turnover
Serum levels of the amino terminal propeptide of type 1
procollagen (P1NP), osteocalcin (OSC), osteoprotegerin (OPG),
C-terminal telopeptides of type I collagen (CTX-I), and tartrate-
resistant acid phosphatase 5b (TRAP5b) were measured using
mouse sandwich ELISA kits from Biomedical Technologies
(Stroughton, MA, USA) or Immunodiagnostic System (Fountain
Hills, AZ, USA). The manufacturers’ protocols were followed, and
all samples were assayed in duplicate. A standard curve was
generated from each kit, and the absolute concentrations were
extrapolated from the standard curve. The coefficients of
variation (CVs) for interassay and intraassay measurements were
less than 10% for all assays and are similar to the manufacturers’
references.(18,19)
Bone histomorphometry
After fixation in 4% paraformaldehyde, the right distal femurs
were dehydrated in graded concentrations of ethanol and xylene
and embedded undecalcified inmethyl methacrylate. The frontal
sections (8mm thick) were cut using a vertical-bed microtome
(Leica/Jung 2255, Bannockbum, IL, USA) and affixed to slides
coated with a 2% gelatin solution. Unstained 8mm thick sections
were used for assessing fluorochrome labeling and dynamic
changes in bone. Bone histomorphometry was performed using
semiautomatic image analysis (Bioquant Image Analysis Corpo-
ration, Nashville, TN, USA) linked to a microscope equipped with
transmitted and fluorescent light. The analyses were performed
in the secondary spongiosa of the distal femurs that included
trabecular area between 100 and 300mm distal to the growth
plate and excluding the cortex. Bone turnover measurements
included single- (sL.Pm) and double-labeled perimeter (dL.Pm),
interlabel width (Ir.L.Wi), and osteoclast surface. These indices
were used to calculate mineralizing surface (MS/BS) and mineral
apposition rate (MAR), bone formation rate (BFR/BS), and
percentage of osteoclast surface (Oc.S).(17–19)
RNA preparation and RT-PCR
Tibiae were dissected free of the articular cartilage and soft tissue
and then flash frozen in liquid nitrogen. Total RNA from long
bone and bone marrow were isolated using a modified two-step
purification protocol employing homogenization (PRO250
Homogenizer, 10mm 105mm generator, PRO Scientific IN,
Oxford, CT, USA) in Trizol (Invitrogen, Carlsbad, CA, USA) followed
by purification over a Qiagen RNeasy column (Qiagen, GmbH,
Hilden, Germany). Real-time PCR was carried out on an ABI Prism
7300 (Applied Bioscience, Foster City, CA, USA) in a 25mL192 Journal of Bone and Mineral Researchreaction consisted of 12.5mL 2 SYBER Green Mix (SABioscience,
Inc., Frederick, MD, USA), 0.2mL cDNA, 1mL primer pair mix, and
11.3mL H2O. Primer sets for real-time PCR were purchased from
Superarray (Frederick, MD, USA). All the test genes were
expressed relative to a control gene, b-actin or GAPDH, using
the delta-delta Ct method. The results were expressed as fold
changes from WT group, where fold change is 2DDCt.
Primary bone marrow stromal cell culture
Bonemarrow cells were harvested from 14-week-oldWT or sFRP1
Tg mice of both sexes. After removing the soft tissue, the bone
marrow from the left femurs was flushed out several times in a
solution of PBS, antibiotics (penicillin-streptomycin, 20% by
volume), and Fungizone (5% by volume) under sterile conditions.
The cells were plated in primary medium at 10 106 in 60mm
dishes or 3 106 in six-well plates in primary medium with a-
MEM culture medium, 10% fetal bovine serum, 1% antibiotics
(penicillin-streptomycin), and 0.1% Fungizone. The primary
medium was removed on day 5, leaving only the adherent cells
on the plate. Then the cells were replenished with the secondary
medium containing all the ingredients of the primary medium
plus 50mg/mL ascorbic acid and 10mM b-glycerophosphate. Cell
proliferation was measured on day 5 using the BrdU Immuno-
fluorescence Assay Kit from Roche Applied Science (Indianapolis,
IN, USA). On day 14 of the culture, alkaline phosphatase (ALP)
levels were measured by incubating the cells with p-nitrophenyl
phosphate substrate (Sigma-Aldrich, St. Louis, MO, USA) at room
temperature for 30 minutes. The optical absorbance was read at
405 nm. After the absorbance was taken, protein concentrations
from these wells were measured with the Bio-Rad DC protein
assay kit (Bio Rad, Hercules, CA, USA) using bovine serum
albumin as standard. The ALP activities were normalized to
protein content. ALP value was expressed as amount of ALP that
hydrolyzes 1mmol p-nitrophenol/mg protein per minute.
Another set of cells was fixed and stained for ALP. On day 21
of the cell culture, a set of cells was fixed in 10% neutral buffered
formalin and stained with alizarin red (AR) to monitor
mineralization nodule formation
Western blots/antibodies
Protein lysates from various mouse tissues were prepared by
homogenizing 10 to 20mg of tissue from WT or sFRP1 Tgmice in
cold RadioImmuno Precipitation Assay (RIPA) lysis buffer. Debris
was removed by centrifugation, and protein concentration was
measured by the BioRad DC kit (Bio Rad). Immunoprecipitates
were analyzed by SDS-PAGE and Western blot analyses using
standard conditions and the following antibodies: rabbit
polyclonal anti-sFRP1 (Abcam, 1:230), mouse monoclonal anti-
active dephosphorylated b-catenin (Upstate, 1:200), rabbit
polyclonal anti-GAPDH (1:200), and normal mouse or rabbit
IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immune
complexes were visualized by incubation with horseradish
peroxidase–conjugated secondary antibody. After washing,
protein bands were detected with a chemiluminescence (ECL)
detection system (Amersham Biosciences, Piscataway, NJ, USA).
Quantification of the intensity of the bands in the autoradio-
grams was performed using a Kodak imaging system andYAO ET AL.
analyzed by SCION IMAGE (Frederick, MD, USA). Normalization
was performed with GAPDH antibody.
Statistics
The group means, standard deviations, and percent differences
between the sFRP1 Tg and the WT animals were calculated for
all the outcome variables. The effects of genotype (WT and
sFRP1 Tg), treatment (vehicle and PTH), sex (male and female),
and their interactions were analyzed using a multiple analysis of
variance (MANOVA, SPSS 12, SPSS, Chicago, IL, USA). Differences
were considered significant at p< .05.
Results
Body weights and hindlimb lengths were similar between WT
and sFRP1 Tg mice for both females and males. RT-PCR revealed
increased sFRP1 gene expression in lung, liver, spleen, kidney,
ovary/testis, and bone in both female and male sFRP1 Tg mice
(range 1.2- to 5-fold) compared with WT controls. Western
blotting for sFRP1 in these various tissues (i.e., heart, kidney,
bone/bone marrow, serum) confirmed the PCR changes (see
Fig. 1B, C).
Mice with overexpression of sFRP1 develop osteopenia
and have lower bone formation in both sexes
mCT analysis was performed on the distal femoral metaphyses
(DFMs) and the fifth lumbar vertebral bodies (LVB5s) from
14-week-old mice. The trabecular bonemass (BV/TV) in the DFMs
and LVB5s was 22% and 9% lower in the female sFRP1 Tgmice. In
the male sFRP1 Tg mice, BV/TV was 51% and 33% lower in the
DFMs and LVB5s, respectively, compared with the WTmice. Bone
lose was associated with reduced trabecular thickness (Tb.Th) in
the sFRP1 Tg mice. Midshaft femoral cortical bone thickness wasTable 1. Trabecular Architectural Changes in the Distal Femoral Met
Groups BV/TV (%) Tb
Females
WTþ Vehicle (n¼ 12) 25.9 1.6 5
Tgþ Vehicle (n¼ 11) 20.2 2.7 4
WTþ PTH (n¼ 9) 39.6 7.1 6
Tgþ PTH (n¼ 10) 21.3 6.1 5
Males
WTþ Vehicle (n¼ 11) 24.8 9.8 5
Tgþ Vehicle (n¼ 12) 12.1 2.3 4
WTþ PTH (n¼ 11) 62.3 13.7 6









Tg, sFRP1-trangenic; BV/TV: bone volume; Tb.N: trabecular number; Tb.Th: trab
presented as Mean standard deviation.
OVEREXPRESSION OF SFRP1 INHIBITS BONE FORMATION13% lower in female and 21% lower in male sFRP1 Tg mice
compared with the WT mice (Tables 1 and 2 and Fig. 2).
P1NP and OPG, indicators for osteoblast activity, did not differ
between the sFRP1 Tg and WT mice in females. Osteocalcin, a
bone marker associated with osteoblast maturation, decreased
by 33% in female sFRP1 Tg mice compared with the WT female
mice (p< .05). However, in male mice, P1NP, osteoclacin, and
OPG decreased by 63%, 12%, and 20%, respectively, in the
sFRP1 Tg mice compared with the WT mice (p< .05) (Table 3).
Surface-based bone formation (BFR/BS), measured by histomor-
phometry, decreased by 68% and 48% in female and male
sFRP1 Tgmice respectively, comparedwith their sex-matchedWT
controls (see Table 3).
Overexpression of sFRP1-inhibited osteoblast
differentiation and function
In order to evaluate the effects of systemic sFRP1 overexpression
on osteoblastogenesis in vitro, we collected bone marrow cells
and cultured the cells in osteogenic medium. Cell proliferation
was measured by BrdU incorporation on day 5 of the culture, and
osteogenic differentiation was determined by measuring both
ALP and mineralization nodule formation with AR staining. Cell
proliferation was 46% lower in female and 64% lower in male
sFRP1 Tg–derived cells compared with WT-derived cell cultures
(Fig. 3A). On day 14 of the cell culture, in cells derived from
sFRP1 Tg mice, ALP value was about 30% lower in both females
and the males compared with WT male mice (see Fig. 3B), and
the cells had less ALP-positive colony formation (see Fig. 3C).
Cells derived from sFRP1 Tg mice had lower mineralization
nodule formation, which was about 50% lower in the females
and males compared with WT male mice (see Fig. 3D).
We also evaluated osteoblast differentiation andmaturation in
vivo. We extracted RNA from the whole bone (tibiae) andaphyses
.N (#/mm) Tb.Th (mm) Ct.Th (mm)
.1 0.2 56.6 1.8 160 5
.7 0.4 54.1 2.0 139 15
.3 0.9 71.0 11.1 170 4
.3 1.2 61.1 18.6 143 16
.0 0.3 52.8 9.0 164 12
.7 0.6 41.4 2.7 129 14
.2 0.8 116.6 8.6 254 23








ecular thickness; Ct.Th, cortical bone thickness. NS, non-significant. Data is
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Table 2. Trabecular Architectural Changes in the 5th Lumbar
Vertebral Bodies
Groups BV/TV (%) Tb.N (#/mm) Tb.Th (mm)
Females
WTþ Vehicle (n¼ 12) 22.6 2.8 4.7 0.9 49.1 2.6
Tgþ Vehicle (n¼ 11) 20.5 3.2 4.7 0.5 48.6 1.9
WTþ PTH (n¼ 9) 29.3 8.0 5.3 1.0 55.2 5.6
Tgþ PTH (n¼ 10) 21.1 1.1 4.7 1.2 47.4 8.0
Males
WTþ Vehicle (n¼ 11) 21.1 2.2 4.9 0.1 46.8 2.7
Tgþ Vehicle (n¼ 12) 14.1 3.7 4.7 0.3 40.3 4.1
WTþ PTH (n¼ 11) 49.4 16.6 5.3 0.4 128.9 10.2
Tgþ PTH (n¼ 10) 21.7 5.4 5.1 0.8 44.3 3.7
MANOVA
Genotype 0.04 NS NS
Sex NS NS NS
GenotypeSex 0.02 NS 0.01
PTH 0.01 NS 0.04
PTHGenotype NS NS NS
PTHSex NS NS 0.03
PTHGenotypeSex NS NS NS
Tg, sFRP1-trangenic; BV/TV: bone volume; Tb.N: trabecular number;
Tb.Th: trabecular thickness. NS, non-significant. Data is presented as
Mean standard deviation.performed real-time PCR on selected gene markers for
osteoblast differentiation and maturation (Runx2, Osterix, and
Osteocalcin), key regulators in Wnt signaling (Lrp5 and Lrp6), and
the bone turnover cytokines (RANKL and OPG). OsteocalcinFig. 2. Representative mCT images of the distal femoral trabecular bone
from WT and sFRP1 Tg mice at the age of 14 weeks. Scale bars: 1.0mm.
194 Journal of Bone and Mineral Researchexpression was decreased in the female sFRP1 Tg mice, whereas
all three osteoblastic maturation gene markers were decreased
one- to threefold in the male sFRP1 Tg mice compared with the
WT controls (Fig. 4A). The expression levels of Lrp5 and Lrp6,
coreceptors for Wnt/b-catenin signaling, were significantly lower
(about threefold) in female and more than sixfold lower in male
sFRP1 Tg mice compared with WT mice (see Fig. 4A). The
expression levels of RANKL and OPG were 6- to 14-fold lower in
the sFRP1 Tgmice compared with WT mice (see Fig. 4A). ‘‘Active’’
(nonphosphorylated) b-catenin expression was about 40% lower
in bone/bone marrow in female sFRP1 Tg mice and was about
60% lower in male sFRP1 Tg mice compared with WT mice (see
Fig. 4B).
Overexpression of sFRP1 did not affect bone resorption in
vivo but induced higher osteoclastogenesis in vitro
compared with the WT mice
The sFRP1 overexpression increased TRAP5b, CTX-1, and
osteoclast surface (Oc.S) by 56%, 34% and 38%, respectively,
in female sFRP1 Tg mice compared with WT controls. In male
sFRP1 Tg mice, sFRP1 overexpression increased TRAP5b, CTX-1,
and osteoclast surface by 48%, 39% and 37%, respectively,
compared with WT controls (Table 4).
Overexpression of sFRP1 attenuated the increase in bone
mass and bone formation following PTH treatment that
was observed in the WT controls
Since sFRP1 is associated with a reduction in osteoblast
maturation and function, we hypothesized that sFRP1 Tg mice
may have a reduced anabolic response to PTH treatment
compared with WT controls. In female WT mice treated with PTH
for 14 days, BV/TV of the DFMs and LVB5s was 53% and 30%
higher than in the vehicle-treatedWT group (see Table 1). In male
WT mice treated with PTH, BV/TV of the DFMs and LVB5s was
151% and 134% higher than in male vehicle-treated WT mice
(see Table 1).
In female PTH-treated WT mice, bone-formation parameters,
including serum P1NP, osteocalcin, OPG, and BFR/BS, were
increased by 257%, 40%, 9%, and 19%, respectively, compared
with WT mice. In female PTH-treated sFRP1 Tg mice, these
parameters were increased by 63%, 47%, 4% and 125%,
respectively, compared with the vehicle-treated sFRP1 Tg mice
(see Table 3). In male WT mice treated with PTH, the percentage
increases in PINP, osteocalcin, OPG, and BFR/BS following PTH
treatment were 148%, 85%, 44% and 89% compared with the
male vehicle-treated WT mice. PTH treatment in sFRP1 Tg male
mice increased these parameters by 229%, 92%, 60% and 17%,
respectively, compared with vehicle-treated sFRP1 Tg mice (see
Table 3).
Osteogenic marker gene expression in female and male WT
mice treated with PTH were increased (range 1.6- to 2-fold)
compared with vehicle-treated WT mice. PTH treatment in WT
mice decreased RANKL expression by about 1.5-fold, whereas it
increased OPG expression by 2-fold. However, the gene
expression patterns in sFRP1 Tg female and male mice treated
with PTH were similar to those of vehicletreated sFRP1 Tg mice
(see Fig. 4A). PTH treatment increased active b-cateninYAO ET AL.
Table 3. Bone Formation Parameters
Groups P1NP (ng/mL) Osteocalcin (ng/mL) OPG (ng/mL) BFR/BS (mm/d)
Females
WTþ Vehicle (n¼ 12) 7.5 1.7 21.6 3.4 2.12 0.7 0.37 0.1
Tgþ Vehicle (n¼ 11) 8.1 1.6 14.4 2.4 1.98 0.05 0.12 0.1
WTþ PTH (n¼ 9) 26.8 4.6 30.3 6.8 2.31 0.5 0.44 0.1
Tgþ PTH (n¼ 10) 13.2 3.0 21.2 7.0 2.06 0.5 0.27 0.1
Males
WTþ Vehicle (n¼ 11) 25.1 1.4 11.8 1.5 1.95 0.2 0.55 0.1
Tgþ Vehicle (n¼ 12) 9.2 1.3 10.3 1.7 1.55 0.3 0.29 0.3
WTþ PTH (n¼ 11) 62.4 10.3 21.8 5.6 2.82 0.6 1.04 0.2
Tgþ PTH (n¼ 10) 30.3 13.2 19.8 5.7 2.49 0.9 0.34 0.1
MANOVA
Genotype 0.01 0.05 0.05 0.001
Sex 0.0001 0.05 NS 0.01
GenotypeSex 0.03 NS 0.02 0.02
PTH 0.0001 0.03 0.01 0.001
PTHGenotype 0.03 NS NS 0.05
PTHSex 0.01 NS NS 0.02
PTHGenotypeSex 0.05 NS NS 0.01
BFR/BS: Bone formation rate/bone surface; NS, non-significant. Data is presented as Mean standard deviation.concentration in bone and bone marrow by more than twofold
in WT mice but failed to do so in sFRP1 Tg mice (see Fig. 4B).
After determining that sFRP1 overexpression impaired
PTH-induced bone formation, we then analyzed its effect on
bone resorption. PTH tended to increase these bone-resorption
parameters in WT mice by 10% to 50%, but these changes
did not reach significant levels. In the sFRP1 Tg mice,
PTH treatment did not change these bone-resorption
parameters compared with vehicle treatment. However,
PTH treatment further increased TRAP5b, CTX-1, and Oc.S inFig. 3. Bone stromal cell culture from 14-week-oldWT or sFRP1 Tgmice. (A) Cell p
WT or sFRP1 Tgmice were cultured on a 96-well plate for 4 days, and then the cel
measured with a microplate reader. (B–D) Bone marrow cells were extracted an
ALP levels were obtained (B), the cells were stained with ALP staining to m
performed at day 21 to monitor mineralization nodule formation (D).
OVEREXPRESSION OF SFRP1 INHIBITS BONE FORMATIONmale sFRP1 Tg mice by 9%, 25%, and 16%, respectively,
compared with the vehicle-treated male sFRP1 Tg mice
(see Table 4).
Discussion
This study determined that overexpression of sFRP1 in mice
results in an osteopenic phenotype characterized by an
inhibition of bone formation, with males being more severelyroliferation inWT or sFRP1 Tgmice. Bonemarrow cells derived from either
ls were incubated with BrdU for 2 hours. Absorbance at 370 to 392 nmwas
d cultured with ascorbic acid and b-glycerophosphate for 14 days. After
onitor ALP-positive colony formation (C). Alizarin red staining (AR) was
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Fig. 4. Expression of several genes that regulate osteoblast maturation and function in whole bone from 14-week-old WT or sFRP1 Tg mice. (A) RNA was
extracted from bone and bone marrow of the tibiae and real-time PCR was performed to monitor gene expression that was associated with osteoblast
differentiation and maturation (Runx2, Osterix, Osteocalcin, RANKL, and OPG) or Wnt signaling (Lrp5 and Lrp6). (B) Protein was extracted from bone and
bone marrow from WT or sFRP1 Tg mice and subjected to Western blotting of the active dephosphorylated b-catenin. ap< .05 from the WT.affected than females. In addition, sFRP1 overexpression
attenuated PTH initial anabolic action on bone, as characterized
by substantially less gain in bone mass and lower osteoblast
maturation gene activations in both sexes. PTH further increased
osteoclast surface and bone resorption (CTX-1) in the male
sFRP1 Tg mice, suggesting that increased bone resorption alsoTable 4. Bone Resorption Parameters
Groups TRAP5b (U/L) CTX-1(U/L) Oc.S (%)
Females
WTþ Vehicle (n¼ 12) 3.9 0.8 9.6 2.0 3.7 0.7
Tgþ Vehicle (n¼ 11) 6.1 0.9 12.9 2.1 5.1 0.3
WTþ PTH (n¼ 9) 5.3 1.7 11.9 1.1 4.1 0.1
Tgþ PTH (n¼ 10) 5.6 1.2 13.0 3.3 5.7 0.1
Males
WTþ Vehicle (n¼ 11) 3.1 1.3 8.1 0.8 4.5 0.6
Tgþ Vehicle (n¼ 12) 4.6 0.9 11.3 2.1 6.8 0.9
WTþ PTH (n¼ 11) 4.9 0.8 10.1 2.1 5.8 0.1
Tgþ PTH (n¼ 10) 5.0 1.8 14.2 1.8 7.9 0.4
MANOVA
Genotype 0.01 0.05 0.001
Sex NS NS NS
GenotypeSex NS NS 0.05
PTH NS NS NS
PTHGenotype NS 0.03 0.04
PTHSex NS NS 0.01
PTHGenotypeSex NS NS 0.001
Tg, sFRP1-trangenic; Oc.S, osteoclast surface. NS, non-significant. Data is
presented as Mean standard deviation.
196 Journal of Bone and Mineral Researchmay play a role in the reduced bone anabolic effects observed in
male transgenic mice.
Effects of overexpression of sFRP1 in bone
The phenotype changes we have described for sFRP1 Tg mice
are different from those reported for the sFRP1 knockout
mouse.(10,11) The sFRP1 knockout (KO) mice and WT mice had
similar trabecular bone mass at 3 months of age, and age-related
bone loss was observed in the WT mice but not in the sFRP1 KO
mice. However, at 14 weeks of age, sFRP1 Tg mice had a
significantly lower amount of trabecular and cortical bone mass,
with the male sFRP1 Tg mice being more severely osteoporotic
than the female mice. The sFRP1 Tg mice had lower parameters
of bone formation measured by both serum bone-formation
markers and surface-based bone histomorphometry compared
with WT mice. Lower bone formation accounts for most of bone
loss seen in these sFRP1 Tg mice.
The sFRP1 Tg mice had broad tissue distribution increases in
sFRP1 expression. Lung, liver, kidney, ovary/testis, and bone had
1.6- to 4-fold higher sFRP1 levels than the WT mice. The b-
catenin levels in bone and bone marrow were lower in the
sFRP1 Tg mice, especially the males. Our study found that
systemic overexpression of sFRP1 lowered Wnt/b-catenin
signaling in bone and inhibited bone marrow cell proliferation
and osteogenic differentiation that resulted in lower osteoblast
maturation and function. Although our transgenic model
was not specific to osteoblasts, our findings suggest that
systemic sFRP1 overexpression appeared to affect osteogenic
differentiation and bone formation. Recently, Bodine and
colleagues reported that a small molecule inhibitor (diarylsulfoneYAO ET AL.
Fig. 5. Expression of several genes that regulate osteoblast maturation and function in whole bone from 12-week-old WT or sFRP1 Tg mice treated with
PTH for 2 weeks. (A) RNA was extracted from bone and bone marrow from the tibiae of WT or sFRP1 Tg mice treated with PTH. Real-time PCR was
performed to monitor gene expression that was associated with osteoblast differentiation and maturation (Runx2, Osterix, Osteocalcin, RANKL, andOPG) or
Wnt signaling (Lrp5 and Lrp6). (B) Protein was extract from bone and bone marrow of WT or sFRP1 Tg mice treated with PTH and subjected to Western
blotting of the active dephosphorylated b-catenin. bp< 0.05 from vehicle-treated WT or sFRP1 Tg mice.sulfonamide) that bound to human sFRP1 inhibited canonical
Wnt signaling measured by TCF-luciferase reporter assay in
vitro.(15) Although an in vivo evaluation of bone effects is not yet
available for this sFRP1 inhibitor, it is possible that selective
inhibition of sFRP1 may be a potential target to stimulate Wnt
signaling that increases bone formation.
Wnt/b-catenin signaling regulates both mesenchymal stem
cells’ commitment to osteoblast differentiation and osteoclast
maturation and activity through the OPG/RANKL system.(20–22)
Secreted FRP1 can directly bind RANKL(13) and/or inhibit the
fusion of mononuclear cells,(14) thereby inhibiting osteoclast
formation. We found that in vivo bone resorption was higher in
the sFRP1 Tg mice. Our findings that sFRP1 overexpression
increased bone resorption in the male mice were similar to the
findings of Diarra and colleagues,(23) who reported the effects of
Dkk-1, another Wnt antagonist, on bone resorption. Dkk-1
overexpression stopped osteoblast maturation at the preosteo-
blast stage. As a result, more RANKL and less OPG were
produced, resulting in increased or accelerated osteoclastogen-
esis.(23) Secreted FRP1 may bind to the soluble Wnt agonists and
prevent Wnt signaling through the frizzled/Lrp5/Lrp6, which
would arrest osteoblast proliferation and differentiation. The
decrease in mature osteoblasts might enhance bone resorption
by lowering the production of OPG, increasing the RANKL/OPG
ratio, and permitting RANKL-induced osteoclastogenesis.(24)
Interestingly, sexual dimorphism inWnt/b-catenin signaling of
bone formation and bonemass often exists. In humans, there is aOVEREXPRESSION OF SFRP1 INHIBITS BONE FORMATIONstronger association between Lrp5 polymorphism and bone
mass in males compared with females.(25–27) In females, two
common variants of Lrp5 were reported to be associated with
vertebral fracture risk.(28) Sexual dimorphism in Wnt/b-catenin
signaling also has been reported in mice that have been
genetically modified for inhibition of Wnt/ b-catenin signaling. In
mice null for Lrp5, lumbar vertebral trabecular bone mass was
10% lower in females and 43% lower in males compared with
their aged-matched WT counterparts, with lumbar compression
strength lowered by nearly 30% in females and by 50% in
males.(29) On the other hand, in mice that overexpressed LRP5
G171V, trabecular bone mass was twofold higher in both the
female and male transgenic mice at 3 months of age.(30–32)
However, when the mice aged, the trabecular bone mass was
about 100% higher in female and 162% higher in male
transgenic mice compared with WT mice.(31) Adult female sFRP1
KO mice had 179% more trabecular bone mass and male sFRP1
KO mice had 142% more trabecular bone mass than WT controls
by 35 weeks of age.(11) Additional experiments are now under
way to investigate the sexual differences of Wnt/b-catenin
signaling in bone.
Effects of sFRP1 overexpression on bone
response to PTH
PTH is a known anabolic agent for bone because it increases
bone osteoblast maturation and osteoblast activity and prolongsJournal of Bone and Mineral Research 197
osteoblast lifespan.(33–36) PTH anabolic effects are partially
mediated though the Wnt signaling pathway. PTH treatment
directly increased the levels of b-catenin and the transcriptional
activity of TCF/LEF in osteoblastic cell lines.(37,38) PTH also may
achieve its anabolic effects partially by the suppression of
Sost(19,39–41) and Dkk1(19,37) transcription. Interestingly, mice null
for Lrp5, a coreceptor for Wnt, did not have an increase in bone
mass with PTH treatment.(29,42) However, another coreceptor for
Wnt, Lrp6, was reported to form a receptor complex with type 1
parathyroid hormone receptor (PTH1R) and increase osteogen-
esis. This Lrp6/PTH1R signaling pathway may help to explain
PTH’s anabolic action on bone.(43) When we treated sFRP1 Tg and
WT mice with PTH for a relatively short period (14 days), we
found that sFRP1 overexpression inhibited the initial bone
anabolic response to intermittent PTH treatment. Interestingly, in
sFRP1 KO mice, PTH also had less anabolic effects on bone.(12)
Our results and studies from sFRP1 KO mice suggest that PTH
downregulation of sFRP1 is required for stimulation of the Wnt
signaling needed for osteoblastogeneis. In the KO mice, bone
mass is already high owing to an increased Wnt signaling;
consequently, the additional effects of PTH on Wnt signaling
result in only a minor anabolic effect. In overexpressing mice,
Wnt signaling is low, and and without the suppressive effects of
the hormone on sFRP1, full PTH stimulation of Wnt signaling is
delayed
Once osteoblasts begin to differentiate into the preosteo-
blasts, they synthesize RANKL, which is the most potent activator
of osteoclast maturation and activity. Mature osteoblasts,
defined by gene expression of osterix and ALP, do not synthesize
RANKL and instead synthesize OPG, an inhibitor of RANKL that
belongs to the tumor necrosis factor (TNF) receptor family.(44,45)
We found that sFRP1 overexpression lowered OPG mRNA
expression to a larger degree than it lowered RANKL expression,
suggesting that sFRP1 overexpression inhibits osteoblast
maturation more than its inhibition on osteoblast differentiation.
Less OPG production in return potentiated bone resorption.
In our transgenic model, sFRP1 levels were higher in the
tissues (bone and bone marrow), as well as in the circulation
(sFRP1 in serum). A targeted expression of sFRP1 to cells of the
osteoblast lineage will need to be examined to study the direct
effects of sFRP1 on osteoblast. One question that remains
unanswered is whether sFRP1 works at the level of bone/bone
cells or through some other tissue site, as suggested for the role
of Lrp5 in regulation of bone mass.(46) While we have no
evidence to oppose such a possibility in the case of sFRP1
overexpression, the fact that sFRP1 works by binding to Wnt and
thereby decreasing intracellular b-catenin levels, rather than
targeting one of the Lrp5/Lrp6 coreceptors, would seem to favor
a more direct mechanism acting on the bone compartment.
This study has a number of strengths, including the in vivo
and in vitro assessments of sFRP1 overexpression on bone
metabolism. However, there are also a number of shortcomings.
We evaluated only 12- to 14-week-old animals in this study and
were not able to report age-related changes following sFRP1
overexpression. Our PTH treatment period was relatively short
and only allowed us to study the mechanistic aspects of the
interaction. We observed a delay in the response of bonemass to
PTH treatment in the sFRP1 Tg mice. However, since increases in198 Journal of Bone and Mineral Researchbone formation parameters were similar between the genotypes
following PTH treatment, it is likely that longer PTH treatment or
higher dose of PTH may overcome the inhibition of sFRP1
overexpression on osteogenesis and bone formation. In addition,
we did not evaluate the effects of sFRP1 antibody or the addition
of Wnt protein in the cultures. Evaluating these effects may
enable us to better understand the mechanisms of the sFRP1’s
impact on osteoblastogenesis.
In summary, systemic overexpression of sFRP1 inhibited
the osteoblast maturation and function in bone. The sFRP1
overexpression also attenuated the PTH rapid effects on bone
augmentation. The sex difference in the skeletal phenotypes of
this sFRP1 Tg mouse strain is unexpected and warrants further
investigation.
Disclosures
The authors state that they have no conflicts of interest.
Acknowledgments
This work was funded by National Institutes of Health (NIH)
Grants NIAMS- R01 AR043052-07 and K24-AR-048841 (to NEL)
and 1K12HD05195801, which is cofunded by National Institute of
Child Health and Human Development (NICHD), the Office of
Research on Women’s Health (ORWH), the Office of Dietary
Supplements (ODS), and the National Institute of Aging (NIA)
and Endowed Chair in Aging provided to Dr. Nancy Lane by the
University of California at Davis Medical School.
References
1. Fuerer C, Nusse R, Ten Berge D. Wnt signalling in development and
disease. Max Delbruck Center for Molecular Medicine Meeting on
Wnt Signaling in Development and Disease. EMBO Rep. 2008;9:134–
138.
2. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5)
affects bone accrual and eye development. Cell. 2001;107:513–523.
3. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL
receptor-related protein 5 gene results in the autosomal dominant
high-bone-mass trait. Am J Hum Genet. 2002;70:11–19.
4. Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblasto-
genesis and bone mass by Wnt10b. Proc Natl Acad Sci USA.
2005;102:3324–3329.
5. Andrade AC, Nilsson O, Barnes KM, Baron J. Wnt gene expression in
the post-natal growth plate: regulation with chondrocyte differentia-
tion. Bone. 2007;40:1361–1369.
6. Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical
Wnt signaling in specification, differentiation and maintenance of
osteoblast progenitors. Development. 2006;133:3231–3244.
7. Dong YF, SoungDo Y, Schwarz EM, O’Keefe RJ, Drissi H. Wnt induction
of chondrocyte hypertrophy through the Runx2 transcription factor.
J Cell Physiol. 2006;208:77–86.
8. Glass DA 2nd, Bialek P, Ahn JD, et al. Canonical Wnt signaling in
differentiated osteoblasts controls osteoclast differentiation. Dev
Cell. 2005;8:751–764.
9. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt
inhibition: new functions of secreted frizzled-related proteins in
development and disease. J Cell Sci. 2008;121:737–746.YAO ET AL.
10. Bodine PV, Billiard J, Moran RA, et al. The Wnt antagonist secreted
frizzled-related protein-1 controls osteoblast and osteocyte apopto-
sis. J Cell Biochem. 2005;96:1212–1230.
11. Bodine PV, Zhao W, Kharode YP, et al. The Wnt antagonist secreted
frizzled-related protein-1 is a negative regulator of trabecular bone
formation in adult mice. Mol Endocrinol. 2004;18:1222–1237.
12. Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ, Komm BS. Bone
anabolic effects of parathyroid hormone are blunted by deletion of
the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol.
2007;210:352–357.
13. Hausler KD, Horwood NJ, Chuman Y, et al. Secreted frizzled-related
protein-1 inhibits RANKL-dependent osteoclast formation. J Bone
Miner Res. 2004;19:1873–1881.
14. Liu D, Wise GE. A DNAmicroarray analysis of chemokine and receptor
genes in the rat dental follicle: role of secreted frizzled-related
protein-1 in osteoclastogenesis. Bone. 2007;41:266–272.
15. Bodine P, Stauffer B, Ponce-de-Leon H, Bhat B, Mangine A, Seestaller-
Wehr L. A small molecule inhibitor of the Wnt antagonist secreted
frizzled-related protein (SFRP)-1 stimulates bone formation. J Bone
Miner Res. 2007;22:S4.
16. Gong S, Yang XW, Li C, Heintz N. Highly efficient modification of
bacterial artificial chromosomes (BACs) using novel shuttle vectors
containing the R6Kg origin of replication. Genome Res. 2002;12:
1992–1998 .
17. Lane NE, Yao W, Balooch M, et al. Glucocorticoid-treated mice have
localized changes in trabecular bone material properties and osteo-
cyte lacunar size that are not observed in placebo-treated or estro-
gen-deficient mice. J Bone Miner Res. 2006;21:466–476.
18. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE.
Glucocorticoid excess in mice results in early activation of osteo-
clastogenesis and adipogenesis and prolonged suppression of
osteogenesis: a longitudinal study of gene expression in bone tissue
from glucocorticoid-treated mice. Arthritis Rheum. 2008;58:1674–
1686.
19. Yao W, Cheng Z, Pham A, et al. Glucocorticoid-induced bone loss in
mice can be reversed by the actions of parathyroid hormone and
risedronate on different pathways for bone formation and miner-
alization. Arthritis Rheum. 2008;58:3485–3497.
20. Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-
catenin in postnatal bone acquisition. J Biol Chem. 2005;280:21162–
21168.
21. Boyce BF, Xing L, Chen D. Osteoprotegerin, the bone protector, is a
surprising target for beta-catenin signaling. Cell Metab. 2005;2:344–
345.
22. Goldring SR, Goldring MB. Eating bone or adding it: the Wnt pathway
decides. Nat Med. 2007;13:133–134.
23. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of
joint remodeling. Nat Med. 2007;13:156–163.
24. Huang JC, Sakata T, Pfleger LL, et al. PTH differentially regulates
expression of RANKL and OPG. J Bone Miner Res. 2004;19:235–244.
25. Ferrari SL, Deutsch S, Baudoin C, et al. LRP5 gene polymorphisms and
idiopathic osteoporosis in men. Bone. 2005;37:770–775.
26. Ferrari SL, Deutsch S, Choudhury U, et al. Polymorphisms in the low-
density lipoprotein receptor-related protein 5 (LRP5) gene are asso-
ciated with variation in vertebral bone mass, vertebral bone size, and
stature in whites. Am J Hum Genet. 2004;74:866–875.OVEREXPRESSION OF SFRP1 INHIBITS BONE FORMATION27. Kiel DP, Ferrari SL, Cupples LA, et al. Genetic variation at the low-
density lipoprotein receptor-related protein 5 (LRP5) locus modulates
Wnt signaling and the relationship of physical activity with bone
mineral density in men. Bone. 2007;40:587–596.
28. van Meurs JB, Trikalinos TA, Ralston SH, et al. Large-scale analysis of
association between LRP5 and LRP6 variants and osteoporosis. JAMA.
2008;299:1277–1290.
29. Sawakami K, Robling AG, Ai M, et al. The Wnt co-receptor LRP5 is
essential for skeletal mechanotransduction but not for the anabolic
bone response to parathyroid hormone treatment. J Biol Chem.
2006;281:23698–23711.
30. Akhter MP, Wells DJ, Short SJ, et al. Bone biomechanical properties in
LRP5 mutant mice. Bone. 2004;35:162–169.
31. Babij P, Zhao W, Small C, et al. High bone mass in mice expressing a
mutant LRP5 gene. J Bone Miner Res. 2003;18:960–974.
32. Zhang Y, Wang Y, Li X, et al. The LRP5 high-bone-mass G171V muta-
tion disrupts LRP5 interaction withMesd. Mol Cell Biol. 2004;24:4677–
4684.
33. Hock JM. Anabolic actions of PTH in the skeletons of animals.
J Musculoskelet Neuronal Interact. 2001;2:33–47.
34. Bringhurst FR. PTH receptors and apoptosis in osteocytes.
J Musculoskelet Neuronal Interact. 2002;2:245–251.
35. Turner PR, Mefford S, Christakos S, Nissenson RA. Apoptosis mediated
by activation of the G protein-coupled receptor for parathyroid
hormone (PTH)/PTH-related protein (PTHrP). Mol Endocrinol. 2000;
14:241–254.
36. Karaplis AC, Deckelbaum RA. Role of PTHrP and PTH-1 receptor in
endochondral bone development. Front Biosci. 1998;3:d795–d803.
37. Kulkarni NH, Halladay DL, Miles RR, et al. Effects of parathyroid
hormone on Wnt signaling pathway in bone. J Cell Biochem.
2005;95:1178–1190.
38. Tobimatsu T, Kaji H, Sowa H, et al. Parathyroid hormone increases
beta-catenin levels through Smad3 in mouse osteoblastic cells.
Endocrinology. 2006;147:2583–2590.
39. Bellido T. Downregulation of SOST/sclerostin by PTH: a novel
mechanism of hormonal control of bone formation mediated by
osteocytes. J Musculoskel Neuronal Interact. 2006;6:358–359.
40. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone.
2005;37:148–158.
41. O’Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and
remodeling by PTH receptor signaling in osteocytes. PLoS ONE.
2008;3:e2942.
42. Iwaniec UT, Wronski TJ, Liu J, et al. PTH stimulates bone forma-
tion in mice deficient in Lrp5. J Bone Miner Res. 2007;22:394–402.
43. Wan M, Yang C, Li J, et al. Parathyroid hormone signaling through
low-density lipoprotein-related protein 6. Genes Dev. 2008;22:2968–
2979.
44. Gallagher JC. Advances in bone biology and new treatments for bone
loss. Maturitas. 2008;60:65–69.
45. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel
secreted protein involved in the regulation of bone density. Cell.
1997;89:309–319.
46. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by
inhibiting serotonin synthesis in the duodenum. Cell. 2008;135:825–
837.Journal of Bone and Mineral Research 199
